Celldex Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Celldex Therapeutics kazanç ve gelirin sırasıyla yıllık 26.1% ve 64.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 27.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -169.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

26.1%

Kazanç büyüme oranı

27.2%

EPS büyüme oranı

Biotechs kazanç büyümesi	26.8%
Gelir büyüme oranı	64.6%
Gelecekteki özkaynak getirisi	-169.5%
Analist kapsamı	Good
Son güncelleme	02 Jan 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jun 05

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jul 07

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Apr 21

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Feb 27

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

May 25

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Feb 03

Celldex: Pipeline Of Drug Candidates Is Worth A Look

Feb 01

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

Sep 23

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Sep 15

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:CLDX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	36	-272	-217	-255	5
12/31/2026	3	-274	-234	-190	7
12/31/2025	4	-227	-165	-170	10
12/31/2024	7	-160	-157	-143	10
9/30/2024	10	-154	-160	-158	N/A
6/30/2024	8	-150	-123	-121	N/A
3/31/2024	6	-145	-121	-119	N/A
12/31/2023	7	-141	-109	-107	N/A
9/30/2023	4	-125	-98	-97	N/A
6/30/2023	3	-113	-114	-113	N/A
3/31/2023	3	-119	-110	-108	N/A
12/31/2022	2	-112	-106	-104	N/A
9/30/2022	1	-106	-98	-96	N/A
6/30/2022	1	-100	-79	-78	N/A
3/31/2022	4	-77	-69	-67	N/A
12/31/2021	5	-71	-62	-61	N/A
9/30/2021	8	-72	-53	-52	N/A
6/30/2021	9	-66	-48	-47	N/A
3/31/2021	5	-64	-48	-46	N/A
12/31/2020	7	-60	-42	-40	N/A
9/30/2020	5	-48	-48	-46	N/A
6/30/2020	4	-46	-47	-45	N/A
3/31/2020	5	-46	-46	-45	N/A
12/31/2019	4	-51	-47	-46	N/A
9/30/2019	4	-50	-52	-51	N/A
6/30/2019	5	-46	-55	-54	N/A
3/31/2019	7	-50	-61	-60	N/A
12/31/2018	10	-151	-76	-75	N/A
9/30/2018	11	-146	-80	-79	N/A
6/30/2018	14	-165	N/A	-89	N/A
3/31/2018	15	-177	N/A	-93	N/A
12/31/2017	13	-93	N/A	-100	N/A
9/30/2017	11	-121	N/A	-101	N/A
6/30/2017	9	-125	N/A	-100	N/A
3/31/2017	7	-128	N/A	-113	N/A
12/31/2016	7	-129	N/A	-113	N/A
9/30/2016	7	-129	N/A	-106	N/A
6/30/2016	6	-131	N/A	-110	N/A
3/31/2016	6	-132	N/A	-101	N/A
12/31/2015	5	-127	N/A	-99	N/A
9/30/2015	5	-126	N/A	-107	N/A
6/30/2015	5	-122	N/A	-106	N/A
3/31/2015	4	-118	N/A	-102	N/A
12/31/2014	4	-118	N/A	-102	N/A
9/30/2014	3	-108	N/A	-94	N/A
6/30/2014	3	-103	N/A	-85	N/A
3/31/2014	2	-94	N/A	-82	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CLDX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: CLDX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: CLDX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: CLDX şirketinin gelirinin (yıllık 64.6% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CLDX şirketinin gelirinin (yıllık 64.6% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CLDX 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/12 23:39
Gün Sonu Hisse Fiyatı	2025/01/10 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Celldex Therapeutics, Inc. 19 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jonathan Aschoff	Brean Capital
Kristen Kluska	Cantor Fitzgerald & Co.
David Lebowitz	Citigroup Inc

Celldex Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates increase by 65%

Consensus revenue estimates increase by 65%, EPS downgraded

Price target decreased by 7.6% to US$65.38

Consensus revenue estimates decrease by 20%, EPS upgraded

Price target increased by 9.7% to US$69.43

Consensus revenue estimates increase by 37%, EPS downgraded

Recent updates

Now 25% undervalued after recent price drop

New major risk - Revenue and earnings growth

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought US$308k worth of stock

Consensus revenue estimates increase by 65%

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 65%, EPS downgraded

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Price target decreased by 7.6% to US$65.38

Senior VP & Chief Medical Officer recently sold US$1.6m worth of stock

Chief Commercial Officer & Senior VP notifies of intention to sell stock

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024

Senior VP recently sold US$341k worth of stock

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Consensus revenue estimates decrease by 20%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Price target increased by 9.7% to US$69.43

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.475 million.

Consensus revenue estimates increase by 37%, EPS downgraded

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Price target increased by 7.4% to US$64.00

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023

Price target decreased by 7.4% to US$59.57

Consensus revenue estimates decrease by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Celldex Therapeutics, Inc. Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of Cdx-585 in Patients with Advanced Malignancies

Now 20% undervalued after recent price drop

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622

Consensus revenue estimates increase by 68%, EPS downgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Now 23% undervalued

Consensus revenue estimates increase by 11%, EPS downgraded

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors

Founder exercised options and sold US$576k worth of stock

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1B Study in Chronic Inducible Urticaria At Global Urticaria Forum 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Senior VP notifies of intention to sell stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder